• 1
    Obach RS, Baxter JG, Liston TE, et al. The prediction of human pharmacokinetic parameters from preclinical and in vitro metabolism data. J Pharmacol Exp Ther 1997; 283: 4658.
  • 2
    Miners JO, Veronese ME, Birkett DJ. In vitro approaches for the preclinical prediction of human drug metabolism. Ann Reports Med Chem 1994; 29: 307316.
  • 3
    Houston JB. Utility of in vitro drug metabolism data in predicting in vivo metabolic clearance. Biochem Pharmacol 1994; 47: 14691479.
  • 4
    Wilkinson GR, Shand DG. A physiological approach to hepatic drug clearance. Clin Pharmacol Ther 1975; 18: 377390.
  • 5
    Pang KS, Rowland M. Hepatic clearance of drugs. I. Theoretical considerations of a ‘well-stirred’ model and a ‘parallel tube’ model. Influence of hepatic blood flow, plasma and blood cell binding, and the hepatocellular enzymatic activity on hepatic drug clearance. J Pharmacokinet Biopharm 1977; 5: 625653.
  • 6
    Roberts MS, Rowland M. Correlation between in vitro microsomal enzyme activity and whole organ hepatic elimination kinetics: analysis with a dispersion model. J Pharm Pharmacol 1986; 38: 177181.
  • 7
    Ito K, Iwatsubo T, Kanamitsu S, et al. Quantitative prediction of in vivo drug clearance and drug interactions from in vitro data on metabolism, together with binding and transport. Ann Rev Pharmacol Toxicol 1998; 38: 461499.
  • 8
    Iwatsubo T, Hirota N, Ooie T, et al. Prediction of in vivo drug metabolism in the human liver from in vitro metabolism data. Pharmacol Ther 1997; 73: 147171.
  • 9
    Maenpaa J, Hall SD, Ring BJ, Strom SC, Wrighton SA. Human cytochrome P450 3A (CYP3A) mediated midazolam metabolism. the effect of assay conditions and regioselective stimulation by α–naphthoflavone, terfenadine and testosterone. Pharmacogenetics 1998; 8: 137155.
  • 10
    Miners JO, Mackenzie PI. Drug glucuronidation in humans. Pharmacol Ther 1991; 51: 347369.
  • 11
    Dutton GJ. Glucuronidation of Drugs and Other Compounds. Boca Raton: CRC Press 1980, 2952.
  • 12
    Stagg MP, Cretton EM, Kidd L, Diasio RB, Sommadossi J-P. Clinical pharmacokinetics of 3′-azido3′-deoxythymidine (zidovudine) and catabolites with formation of a toxic catabolite, 3′-amino-3′-deoxythymidine. Clin Pharmacol Ther 1992; 51: 668676.
  • 13
    Klecker RW, Collins JM, Yarchoan R, et al. Plasma and cerebrospinal fluid pharmacokinetics of 3′-azido-3′-deoxythymidine: a novel pyrimidine analog with potential application for the treatment of patients with AIDS an related diseases. Clin Pharmacol Ther 1987; 41: 407412.
  • 14
    Blum MR, Liao SHT, De Miranda P. Pharmacokinetics and bioavailability of zidovudine in humans. Am J Med 1988; 85(Suppl 2A): 189194.
  • 15
    Robson RA, Matthews AP, Miners JO, et al. Characterisation of theophylline metabolism by human liver microsomes. Br J Clin Pharmacol 1987; 24: 293300.
  • 16
    Sim SM, Back DJ, Breckenridge AM. The effect of various drugs on the glucuronidation of zidovudine (azidothymidine; AZT) by human liver microsomes. Br J Clin Pharmacol 1991; 32: 1721.
  • 17
    McLure JA, Miners JO, Birkett DJ. Nonspecific binding of drugs to human liver microsomes. Br J Clin Pharmacol 2000; 49: 453461.
  • 18
    Luzier A, Morse GD. Intravascular distribution of zidovudine: role of plasma proteins and whole blood components. Antiviral Res 1993; 21: 267280.
  • 19
    Howe JL, Back DJ, Colbert J. Extrahepatic metabolism of zidovudine. Br J Clin Pharmacol 1992; 33: 190192.
  • 20
    Miners JO, Lillywhite KJ, Matthews AP, Jones ME, Birkett DJ. Kinetic and inhibitor studies of 4-methylumbelliferone and 1-naphthol glucuronidation in human liver microsomes. Biochem Pharmacol 1988; 37: 665671.
  • 21
    Yun C-H, Song M, Ahn T, Kim H. Conformational change of cytochrome P4501A2 induced by sodium chloride. J Biol Chem 1996; 271: 3131231316.
  • 22
    Fisher MB, Campanale K, Ackermann BL, Vandenbranden M, Wrighton SA. In vitro glucuronidation using human liver microsomes and the pore-forming peptide alamethacin. Drug Metab Disp 2000; 28: 560566.
  • 23
    Bock KW, White INH. UDP-Glucuronosyltransferase in perfused rat liver and in microsomes: Influence of phenobarbital and 3-methylcholanthrene. Eur J Biochem 1974; 46: 451459.
  • 24
    Brunelle FM, Verbeeck RK. Glucuronidation of diflunisal in liver and kidney microsomes of rat and man. Xenobiotica 1996; 26: 123131.
  • 25
    Radominska-Pandya A, Czernik PJ, Little JM, Battaglia E, Mackenzie PI. Structural and functional studies of UDP-glucuronosyltransferases. Drug Metab Rev 1999; 31: 817899.
  • 26
    Blankaert N. Guanosine 5′-phosphate modulates uridine-5′-diphosphate glucuronosyltransferase activities in rat liver microsomes. Gastroenterol 1988; 94: A526.
  • 27
    Mistry M, Houston JB. Glucuronidation in vitro and in vivo. Comparison of intestinal and hepatic conjugation of morphine, naloxone and buprenorphine. Drug Metab Disp 1987; 15: 710717.
  • 28
    Bowalgaha K, Miners JO. The glucuronidation of mycophenolic acid by human liver, kidney and jejunum microsomes. Br J Clin Pharmacol 2001; 52: 605609.
  • 29
    Obach RS. Nonspecific binding to microsomes. Impact on scale-up of in vitro intrinsic clearance to hepatic clearance as assessed through examination of warfarin, imipramine and propranolol. Drug Metab Disp 1997; 42: 13591369.
  • 30
    Burchell B, Brierley CH, Rance D. Specificity of human UDP-glucuronosyltransferases and xenobiotic glucuronidation. Life Sci 1995; 57: 18191131.
  • 31
    Aitkenhead AR, Derbyshire DR, Pinnock DR, Achola K, Smith G. Pharmacokinetics of intravenous naloxone in healthy volunteers. Anesthesiol 1984; 61: A381.
  • 32
    Asali LA, Brown KF. Naloxone protein binding in adult and foetal liver. Eur J Clin Pharmacol 1984; 27: 459463.
  • 33
    Soars MG, Riley RJ, Findlay KAB, Coffey MJ, Burchell B. Evidence for significant differences in microsomal drug glucuronidation by canine and human liver and kidney. Drug Metab Disp 2001; 29: 121126.
  • 34
    Simons PJ, Cockshott ID, Douglas EJ, Gordon EA, Hopkins K, Rowland M. Disposition in male volunteers of a subanaesthetic intravenous dose of an oil in water emulsion of 14C-propofol. Xenobiotica 1988; 18: 429440.
  • 35
    Gepts E, Camu F, Cockshott ID, Douglas EJ. Disposition of propofol administered as constant rate intravenous infusions in humans. Anesth Analg 1987; 66: 12561263.
  • 36
    Servin F, Desmonts JM, Haberer JP, Cockshott ID, Plummer GF, Farinotti R. Pharmacokinetics and protein binding of propofol in patients with cirrhosis. Anesthesiol 1988; 69: 887891.
  • 37
    Hasselstrom J, Sawe J. Morphine pharmacokinetics and metabolism in humans: Enterohepatic cycling and relative contribution of metabolites to active opioid concentrations. Clin Pharmacokinet 1993; 24: 344354.
  • 38
    Milne RW, Nation RL, Somogyi AA. The disposition of morphine and its 3- and 6-glucuronide metabolites in humans and animals, and the importance of metabolites to the pharmacological effects of morphine. Drug Metab Rev 1996; 28: 345472.
  • 39
    Zhou S, Chin R, Kestell P, Tingle MD, Paxton JW. Effects of anticancer drugs on the metabolism of the anticancer drug 5,6-dimethylxanthenone-4-acetic acid (DMXAA) by human liver microsomes. Br J Clin Pharmacol 2001; 52: 129136.
  • 40
    Jameson MB, Thomson PI, Baguley BC, et al. Phase I pharmacokinetic and pharmacodynamic study of 5,6-dimethylxanthenone-4-acetic acid (DMXAA), a novel antivascular agent. Proc Annu Meet Am Soc Clin Oncol 2000; 19: 705.
  • 41
    Miners JO, Valente L, Lillywhite KJ, et al. Preclinical prediction of factors influencing the disposition of 5,6-dimethylxanthenone-4-acetic acid, a new anticancer drug. Cancer Res 1997; 57: 284289.
  • 42
    Rawlins MD, Henderson DB, Hijab AR. Pharmacokinetics of paracetamol (acetaminophen) after intravenous and oral administration. Eur J Clin Pharmacol 1977; 11: 283286.
  • 43
    Miners JO, Attwood J, Birkett DJ. Influence of sex and oral contraceptive steroids on paracetamol metabolism. Br J Clin Pharmacol 1983; 16: 503509.
  • 44
    Kamali F, Fry JR, Bell GD. Salivary secretion of paracetamol in man. J Pharm Pharmacol 1986; 39: 150152.
  • 45
    Gwilt JR, Robertson A, Chesney EW. Determination of blood and other tissue concentrations of paracetamol in dog and man. J Pharm Pharmacol 1983; 15: 440444.
  • 46
    Miners JO, Lillywhite KJ, Yoovathaworn K, Pongmarutai M, Birkett DJ. Characterization of paracetamol UDP-glucuronosyltransferase activity in human liver microsomes. Biochem Pharmacol 1990; 40: 595600.
  • 47
    Schultz P, Dick P, Blaschke TF, Hollister L. Discrepancies between pharmacokinetic studies of amitriptyline. Clin Pharmacokinet 1985; 10: 257268.
  • 48
    Breyer-Pfaff U, Pfandel B, Nill K, et al. Enantioselective amitriptyline metabolism in patients phenotyped for two cytochrome P450 isozymes. Clin Pharmacol Ther 1992; 52: 350358.
  • 49
    Breyer-Pfaff U, Fischer D, Winne D. Biphasic kinetics of quaternary ammonium glucuronide formation from amitriptyline and diphenhydramine in human liver microsomes. Drug Metab Disp 1997; 25: 340345.
  • 50
    Yuen WC, Peck AW. Lamotrigine pharmacokinetics: oral and i.v. infusion in man. Br J Clin Pharmacol 1988; 26: 242P.
  • 51
    Rambeck B, Wolf P. Lamotrigine clinical pharmacokinetics. Clin Pharmacokinet 1993; 25: 433443.
  • 52
    Magdalou J, Herber R, Bidault R, Siest G. In vitro glucuronidation of a novel antiepileptic drug, lamotrigine, by human liver microsomes. J Pharmacol Exp Ther 1992; 260: 11661173.
  • 53
    Miners JO, Robson RA, Birkett DJ. Gender and oral contraceptive steroids as determinants of drug glucuronidation; effects on clofibric acid elimination. Br J Clin Pharmacol 1984; 18: 240243.
  • 54
    Emudianughe TS, Caldwell J, Sinclair KA, Smith RL. Species differences in the metabolic conjugation of clofibric acid and clofibrate in laboratory animals and man. Drug Metab Disp 1983; 11: 97102.
  • 55
    Dragacci S, Hamar-Hansen C, Fournel-Gigleux S, Lafaurie C, Magdalou J, Siest G. Comparative study of clofibric acid and bilirubin glucuronidation in human liver microsomes. Biochem Pharmacol 1987; 36: 39233927.
  • 56
    Vree TB, Van Den Biggelaar-Martea M, Verwy-Van Wissen CPWGM, Vree ML, Guelen PJM. The pharmacokinetics of naproxen, its metabolite O-desmethylnaproxen, and their acyl glucuronides in humans. Effects of cimetidine. Br J Clin Pharmacol 1993; 35: 467472.
  • 57
    Addison RS, Parker-Scott SL, Hooper WD, Dickinson RG. Effect of naproxen co-administration on valproate disposition. Biopharm Drug Dispos 2000; 21: 235242.
  • 58
    Carlile DJ, Hakooz N, Bayliss MK, Houston JB. Microsomal prediction of in vivo clearance of CYP2C9 substrates in humans. Br J Clin Pharmacol 1999; 47: 625636.